Milestone Pharmaceuticals to Present Etripamil Phase 2 Data at the Heart Rhythm Society's 38th Annual Scientific Sessions

April 12, 2017

Data from NODE-1 Trial to be Presented as Part of Late Breaking Oral Session May 11th
More »

Esperion Announces FDA Confirmation Regarding Regulatory Pathway to Approval for an LDL-C Lowering Indication for Bempedoic Acid

March 20, 2017

Global Pivotal Phase 3 Program Design Can Support Approval for an LDL-C Lowering Indication
More »

Esperion Announces Oral Presentation on Genetic Validation of ATP Citrate Lyase Inhibition at the American College of Cardiology 66th Annual Scientific Session

March 6, 2017

Company to Host Webcast on Sunday, March 19, 2017 at 5:30 p.m. Eastern Time
More »